Improved relapse free survival in patients with poor prognosis Ewing's sarcoma after consolidation with hyperfractionated total body irradiation and fractionated high dose melphalan followed by high dose etoposide and hematopoietic rescue.
Bone Marrow Transplantation Program, Heinrich Heine University Medical Center, Düsseldorf, FRG.
S
S
Burdach
C
C
Peters
M
M
Paulussen
W
W
Nürnberger
R
R
Wurm
P
P
Wernet
D
D
Dilloo
R
R
Voehringer
H
H
Gadner
U
U
Göbel
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000401:mortality; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D006085:Graft Survival; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008558:Melphalan / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D012074:Remission Induction; D012512:Sarcoma, Ewing / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D015996:Survival Rate; D014916:Whole-Body Irradiation / Q000009:adverse effects
D007155:Immunologic Factors; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008558:Melphalan